drugset / Trial / NCT01756131
A Single Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of Intramuscular and Subcutaneous Long Acting GSK1265744 in Healthy Subjects
RandomizedSingle-groupSingle-blind
Summary
A single dose escalation study to determine the safety, tolerability, and pharmacokinetic profile of intramuscular and subcutaneous injections of GSK1265744 long acting parenteral (LAP) in healthy subjects. This study consists of a screening visit, a single injection, and follow-up evaluations for a minimum of 12 weeks following the injection.
Timeline
- Start
- 2010-09
- Primary completion
- 2012-12
- Completion
- 2012-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cabotegravir | Small molecule | 100 mg | Intramuscular |
| Subject | Cabotegravir | Small molecule | 200 mg | Intramuscular |
| Subject | Cabotegravir | Small molecule | 400 mg | Intramuscular |
| Subject | Cabotegravir | Small molecule | 800 mg | Intramuscular |